For Transcept Pharmaceuticals, FDA approval of its middle-of-the-night insomnia pill is not the end of the story. The final twist in their thriller is a decision by partner Purdue Pharma due by December 8 on whether to commercialise Intermezzo in the US or hand the rights back.After watching its $30m approval milestone dribble away following two FDA rejections, executives will be anxious for the credits to roll on this unexpectedly long saga with everyone living happily ever after. A negative decision from Purdue would put Transcept in the unenviable position of having to find a new marketing partner for a sleeping pill that has faced multiple safety questions on its path to market (Intermezzo disappointment another rude awakening for Transcept, July 13, 2011).
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions